Details for Patent: 8,815,301
✉ Email this page to a colleague
Which drugs does patent 8,815,301 protect, and when does it expire?
Patent 8,815,301 protects MONOFERRIC and is included in one NDA.
This patent has forty-two patent family members in twenty-five countries.
Summary for Patent: 8,815,301
| Title: | Stable iron oligosaccharide compound |
| Abstract: | The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia. |
| Inventor(s): | Andreasen; Hans (Holb.ae butted.k, DK) |
| Assignee: | Pharmacosmos Holding A/S (Holbaek, DK) |
| Application Number: | 13/138,669 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Process; |
Drugs Protected by US Patent 8,815,301
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacosmos | MONOFERRIC | ferric derisomaltose | SOLUTION;INTRAVENOUS | 208171-003 | Jan 16, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE | ⤷ Sign Up | ||
| Pharmacosmos | MONOFERRIC | ferric derisomaltose | SOLUTION;INTRAVENOUS | 208171-001 | Jan 16, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE | ⤷ Sign Up | ||
| Pharmacosmos | MONOFERRIC | ferric derisomaltose | SOLUTION;INTRAVENOUS | 208171-002 | Jan 16, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,815,301
| PCT Information | |||
| PCT Filed | March 25, 2009 | PCT Application Number: | PCT/DK2009/050069 |
| PCT Publication Date: | September 30, 2010 | PCT Publication Number: | WO2010/108493 |
International Family Members for US Patent 8,815,301
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2411053 | ⤷ Sign Up | C02411053/01 | Switzerland | ⤷ Sign Up |
| Australia | 2009342799 | ⤷ Sign Up | |||
| Brazil | PI0924653 | ⤷ Sign Up | |||
| Canada | 2756580 | ⤷ Sign Up | |||
| China | 102361651 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
